Photocure

Under 1K följer bolaget

PHO

Oslo Børs

Bioteknik & Läkemedel

Hälsovård

Översikt

Ägarlista

Investerarkonsensus

Photocure är verksamt inom medicinteknik. Bolaget specialiserar sig inom lösningar för fotodynamisk teknik. Lösningarna används för behandling av sjukdomar som föranlett cancer i urinblåsan och HPV. Huvudmarknaderna återfinns inom dermatologi och onkologi, där produkterna används av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1993 och har huvudkontor i Oslo, Norge.

Läs mera

Börsvärde

Omsatt (värde)

Omsättning

EBIT%

P/E

Direktavkastnings- %

Finansiell kalender

4.5.

2026

Bolagsstämma '26

7.5.

2026

Delårsrapport Q1'26

29.7.

2026

Delårsrapport Q2'26

Alla

Pressmeddelanden

VisarAlla typer av innehåll

Regulatoriskt pressmeddelandeför 13 timmar sedan

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Photocure

Pressmeddelandeför 13 timmar sedan

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Photocure

Regulatoriskt pressmeddelande2026-03-03 09:35

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Photocure

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

FREE account

Stock market's most popular morning newsletter

Tillgång till analytikerkommentarer och rekommendationer

Vårt eget aktiescreeningsverktyg

PREMIUM account

Alla aktieanalyser och övrigt innehåll

Premiumverktyg (insidertransaktioner och aktiescreeningsverktyg)

Inderes modellportfölj

Skapa användarkonto

Pressmeddelande2026-03-03 09:34

New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Photocure

Pressmeddelande2026-01-12 16:00

Photocure: New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Photocure

Regulatoriskt pressmeddelande2025-12-29 13:22

PHO: Financial calendar

Photocure

Regulatoriskt pressmeddelande2025-12-08 07:00

The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Photocure

Pressmeddelande2025-12-08 07:00

Photocure: The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Photocure

Regulatoriskt pressmeddelande2025-11-19 07:00

PHO: New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Photocure

Pressmeddelande2025-11-19 07:00

Photocure: New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Photocure

Regulatoriskt pressmeddelande2025-10-31 07:24

Photocure

Finansiell kalender

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Välkommen med i Inderes community!

FREE account

PREMIUM account

Photocure: Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe

Photocure ASA: Results for the fourth quarter of 2025

Photocure ASA: Results for the fourth quarter of 2025

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Photocure: New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

PHO: Financial calendar

The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Photocure: The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

PHO: New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Photocure: New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Photocure ASA: Notification of primary insider transaction

Photocure ASA: Notification of primary insider transaction

Photocure ASA: Results for the third quarter of 2025

Photocure ASA: Results for the third quarter of 2025